A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro.
about
Profile of gantenerumab and its potential in the treatment of Alzheimer's diseaseRS-4252 inhibits amyloid beta-induced cytotoxicity in HeLa cells.Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization.Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways.Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB.Identification of compound-protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds.Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.The Wnt signaling pathway: aging gracefully as a protectionist?The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathwaysA "FOXO" in sight: targeting Foxo proteins from conception to cancer.Targeting synaptic dysfunction in Alzheimer's disease therapy.Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease.Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species.6-Ethyl-N,N'-bis(3-hydroxyphenyl)[1,3,5]triazine-2,4-diamine (RS-0466) enhances the protective effect of brain-derived neurotrophic factor on amyloid beta-induced cytotoxicity in cortical neurones.
P2860
Q27027675-459001C5-AE9B-467F-A817-8896C4427F77Q33187556-B7D1BBB6-8E85-482E-A363-BF653095A0B6Q33979228-CE07EC45-4524-4D50-BB7A-3FFDE6FFB5D6Q35879541-84574000-6E9B-4880-B2ED-ACB5A43E7154Q36002858-0B35F40B-E1CD-48D8-B0A1-673406E97E92Q36105215-48A176CE-097A-49FA-B409-453D0873781CQ36727444-02591B1C-8C9F-4B89-BA4C-5D6738EC54A8Q36728844-39617660-526C-4F88-BFC6-4A2DB8DDBDDFQ36836455-EA794355-A524-412E-8555-47140D896E19Q37041649-D7C95658-258E-4A0E-8FC1-730E003FB3B3Q37153195-54A22E48-FD0D-4F49-BE62-375FAE981E97Q38036916-235A74BB-DFCB-414B-B31C-CA0DA18066B7Q39183335-985A7B6F-4759-4EDB-A1EC-09E7AC789B3EQ40393792-D20A0516-429B-4797-B488-C3C49F4B8334Q44693303-F3D09421-F2F0-4EE7-B409-EF15E2F4F6F8
P2860
A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@ast
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@en
type
label
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@ast
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@en
prefLabel
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@ast
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@en
P2093
P1476
A novel compound RS-0466 rever ...... kt signaling pathway in vitro.
@en
P2093
Hiroshi Kogen
Isao Kaneko
Kazuo Koyama
Masaki Meguro
Satoko Nishimura
Shinji Marumoto
Takako Murasugi
Takekazu Kubo
Tomiichiro Oda
Yasuhiro Nakagami
P356
10.1016/S0014-2999(02)02657-2
P407
P577
2002-12-01T00:00:00Z